Cellectis (ALCLS) H1 2026 earnings summary

Executive summary

• Focused on gene-edited allogeneic CAR T-cell therapies and gene therapy candidates, with ongoing BALLI-01 and NATHALI-01 clinical studies.

• Received FDA RMAT designation for lasme-cel in r/r B-ALL, reflecting promising efficacy and manageable safety profile in pivotal Phase 2 BALLI-01 trial.

• Presented full Phase 1 data for lasme-cel and translational data for eti-cel at EHA 2026, with further interim and full datasets expected in Q4 2026.

• No therapeutic product sales; revenue mainly from collaboration agreements, notably with AstraZeneca.

• Cash, cash equivalents, and fixed-term deposits totaled $169 million as of June 30, 2026, providing runway into Q4 2027.

Financial highlights

• Revenues for H1 2026 were $14.5 million, down from $30.2 million in H1 2025, mainly due to lower activity under the AstraZeneca collaboration.

• Net loss for H1 2026 was $39.6 million ($0.39/share), a slight improvement from $41.9 million ($0.42/share) in H1 2025, driven by a $27.3 million improvement in net financial result.

• R&D expenses rose 16% to $52.2 million; SG&A up 16% to $11.3 million year-over-year, mainly due to higher personnel and stock-based compensation.

• Net financial gain of $9.2 million in H1 2026 vs. a loss of $18.1 million in H1 2025, mainly due to EIB warrant revaluation and FX gains.

• Adjusted net loss was $35.6 million ($0.35/share) in H1 2026, compared to $39.6 million ($0.40/share) in H1 2025.

Outlook and guidance

• Cash runway expected to fund operations into Q4 2027, with focus on advancing clinical pipeline and manufacturing capabilities.

• Pivotal Phase 2 BALLI-01 interim analysis and full Phase 1 dataset for NATHALI-01 anticipated in Q4 2026.

• Anticipates continued losses and increased R&D and SG&A expenses as clinical programs advance.

• Additional capital will be needed before commercialization of any product candidates.